In another pilot study evaluating different therapeutic strategies for treatment of SJIA [81], 12 out of 30 patients received IL-1 inhibitors (ANA as initial treatment, eventually switched to CANA). The gene discussed is IL1A; the disease is systemic-onset juvenile idiopathic arthritis.